Plasma neurofilament light chain as prognostic marker of cognitive decline in neurodegenerative diseases, a clinical setting study DOI Creative Commons

Karl Götze,

Agathe Vrillon, Julien Dumurgier

и другие.

Alzheimer s Research & Therapy, Год журнала: 2024, Номер 16(1)

Опубликована: Окт. 19, 2024

Analysis of selected research cohorts has highlighted an association between plasma neurofilament light (NfL) protein and cross-sectional cognitive impairment as well longitudinal decline. However, the findings have yielded inconsistent results regarding its possible application in clinical practice. Despite potential prognostic significance, role NfL daily practice with unselected patients suffering from remains largely unexplored. This retrospective, monocentric study enrolled 320 Alzheimer's disease ([AD], n = 158), dementia Lewy body ([DLB], 30), frontotemporal ([FTD], 32), non-neurodegenerative diseases ([NND], 59) or subjective decline ([SCD], 41). Plasma levels were measured at baseline on Simoa platform. AD, DLB, FTD also analyzed altogether a 'degenerative conditions' subgroup, whereas SCD NND grouped 'non-degenerative subgroup. We assessed relationship performance, including global cognition six specific domains. A subset 239 had follow-up mini-mental state examinations (MMSE) up to 60 months. Models adjusted age, education level, glomerular filtration rate mass index. In patients, negatively associated (β=-1.28 (-1.81 ; -0.75) P < 0.001), memory (β=-1.48 (-2.38 -0.59), language (β=-1.72(-2.49 -0.95) praxis (β=-2.02 (-2.91 -1.13) 0.001) executive functions (β=-0.81, 0.001). Across diagnosis, all but specifically AD (respectively β=-0.71(-1.21 -0.211), 0.005 β=-1.29 (-2.17 -0.42), 0.004), attention LBD (β=-0.81(-1.16 -0.002), 0.03). Linear mixed-effects models showed that predicted MMSE population (βPlasmaNfLxTime=-0.15 (-0.26 -0.04), 0.006), neurodegenerative condition subgroup (βPlasmaNfLxTime=-0.21 (-0.37 − 0.06), 0.007), not our cohort, was faster dementia, which corroborates data obtained cohorts. Yet, predictive accelerated individuals without neurodegeneration, suggesting use neurodegeneration-specific biomarker.

Язык: Английский

Plasma and CSF neurofilament light chain distinguish neurodegenerative from primary psychiatric conditions in a clinical setting DOI Creative Commons
Dhamidhu Eratne, Matthew Kang, Courtney Lewis

и другие.

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Авг. 12, 2024

ABSTRACT INTRODUCTION Many patients with neurodegenerative disorders (ND) face diagnostic delay and misdiagnosis. We investigated blood cerebrospinal fluid (CSF) neurofilament light chain (NfL) to distinguish ND from primary psychiatric (ND), a common challenge in clinical settings. METHODS Plasma CSF NfL levels were measured compared between groups, adjusting for age, sex, weight. RESULTS 337 participants included: 136 ND, 77 PPD, 124 Controls. was 2.5 fold elevated PPD had strong performance (area under the curve, AUC 0.86, 81%/85% specificity/sensitivity) that comparable (2 elevated, 0.89, 95%/71% specificity/sensitivity). Diagnostic especially younger people (40-<60years). Additional findings cut-offs optimised sensitivity specificity, issues important future translation CONCLUSIONS This study adds evidence simple blood-based biomarker assist as screening test neurodegeneration distinction

Язык: Английский

Процитировано

0
A multifactorial lens on risk factors promoting the progression of Alzheimer’s disease DOI

Jenna Parker,

Jose M. Moris, Lily C. Goodman

и другие.

Brain Research, Год журнала: 2024, Номер 1846, С. 149262 - 149262

Опубликована: Окт. 5, 2024

Язык: Английский

Процитировано

0
Plasma neurofilament light chain as prognostic marker of cognitive decline in neurodegenerative diseases, a clinical setting study DOI Creative Commons

Karl Götze,

Agathe Vrillon, Julien Dumurgier

и другие.

Alzheimer s Research & Therapy, Год журнала: 2024, Номер 16(1)

Опубликована: Окт. 19, 2024

Analysis of selected research cohorts has highlighted an association between plasma neurofilament light (NfL) protein and cross-sectional cognitive impairment as well longitudinal decline. However, the findings have yielded inconsistent results regarding its possible application in clinical practice. Despite potential prognostic significance, role NfL daily practice with unselected patients suffering from remains largely unexplored. This retrospective, monocentric study enrolled 320 Alzheimer's disease ([AD], n = 158), dementia Lewy body ([DLB], 30), frontotemporal ([FTD], 32), non-neurodegenerative diseases ([NND], 59) or subjective decline ([SCD], 41). Plasma levels were measured at baseline on Simoa platform. AD, DLB, FTD also analyzed altogether a 'degenerative conditions' subgroup, whereas SCD NND grouped 'non-degenerative subgroup. We assessed relationship performance, including global cognition six specific domains. A subset 239 had follow-up mini-mental state examinations (MMSE) up to 60 months. Models adjusted age, education level, glomerular filtration rate mass index. In patients, negatively associated (β=-1.28 (-1.81 ; -0.75) P < 0.001), memory (β=-1.48 (-2.38 -0.59), language (β=-1.72(-2.49 -0.95) praxis (β=-2.02 (-2.91 -1.13) 0.001) executive functions (β=-0.81, 0.001). Across diagnosis, all but specifically AD (respectively β=-0.71(-1.21 -0.211), 0.005 β=-1.29 (-2.17 -0.42), 0.004), attention LBD (β=-0.81(-1.16 -0.002), 0.03). Linear mixed-effects models showed that predicted MMSE population (βPlasmaNfLxTime=-0.15 (-0.26 -0.04), 0.006), neurodegenerative condition subgroup (βPlasmaNfLxTime=-0.21 (-0.37 − 0.06), 0.007), not our cohort, was faster dementia, which corroborates data obtained cohorts. Yet, predictive accelerated individuals without neurodegeneration, suggesting use neurodegeneration-specific biomarker.

Язык: Английский

Процитировано

0